<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008954</url>
  </required_header>
  <id_info>
    <org_study_id>Attiva-03</org_study_id>
    <nct_id>NCT03008954</nct_id>
  </id_info>
  <brief_title>Effect of GSP3 on Body Weight in Overweight and Obese Subjects</brief_title>
  <acronym>FLOW</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GSP3 on Body Weight in Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelesis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FLOW (First Loss Of Weight) study is designed to assess the effects of repeated&#xD;
      administration of GSP3, an investigational product, on body weight. It is a multicenter,&#xD;
      randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study. FLOW is being&#xD;
      conducted in 5 medical centers in Italy, Czech Republic, and Denmark, and will randomize 123&#xD;
      overweight and obese adult males and females to receive either placebo, GSP3 (2.25g), or GSP3&#xD;
      (3.75g) in addition to a hypocaloric diet (-600 kcal/day) for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Measured at weeks 0,1,2,4,6,8,10,12,13, and follow up (week 14)</time_frame>
    <description>Change from baseline in kilograms and percent (%) weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight responders</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in body weight of at least 5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Measured at weeks 0,1,2,4,6,8,10,12,13, and follow up (week 14)</time_frame>
    <description>Change from baseline in waist circumference (centimeters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fat mass</measure>
    <time_frame>Measured at weeks 0 and 13</time_frame>
    <description>Change in percentage (%) of total mas from baseline in fat- and bone-free fat mass measured by dual energy X-ray absorptiometry (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone-free fat mass</measure>
    <time_frame>Measured at weeks 0 and 13</time_frame>
    <description>Change in percentage (%) of total mas from baseline in fat- and bone-free fat mass measured by dual energy X-ray absorptiometry (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appetite (hunger, satiety, and fullness)</measure>
    <time_frame>Measured at weeks 0,1,2,4,6,8,10,12,13, and follow up (week 14)</time_frame>
    <description>Assessed by self-administered Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in food intake</measure>
    <time_frame>Measured at weeks 0 and 12</time_frame>
    <description>Assessed by 24 hr dietary recall</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma glucose</measure>
    <time_frame>Measured at baseline and week 13</time_frame>
    <description>Change from baseline in millimoles per liter (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in plasma glucose status (normal, impaired, diabetic)</measure>
    <time_frame>Measured at weeks 0 and 13</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum insulin</measure>
    <time_frame>Measured at weeks 0 and 13</time_frame>
    <description>Change from baseline in miliunits per liter (mU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in insulin resistance</measure>
    <time_frame>Measured at weeks 0 and 13</time_frame>
    <description>Change from baseline in homeostatic model assessment of insulin resistance (HOMA-IR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>Measured at weeks 0 and 13</time_frame>
    <description>Measured in percentage (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total cholesterol, serum low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol/HDL ratio, and triglycerides</measure>
    <time_frame>Measured at weeks 0 and 13</time_frame>
    <description>measured in mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Change vital signs: heart rate, supine and standing systolic and diastolic blood pressure (SBP, DBP)</measure>
    <time_frame>Measured at weeks 0,1,2,4,6,8,10,12,13, and follow up (week 14)</time_frame>
    <description>Measured in beats per minute (heart rate) or millimeters of mercury (mmHg) for blood pressure</description>
  </other_outcome>
  <other_outcome>
    <measure>All adverse events (AE), serious adverse events (SAE), and gastrointestinal symptoms</measure>
    <time_frame>Measured at weeks 0,1,2,4,6,8,10,12,13, and follow up (week 14)</time_frame>
    <description>Number and % of subjects with AE/SAEs spontaneously reported; gastrointestinal symptoms solicited via questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum sodium</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline in millimoles per liter (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum potassium</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum coloride</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum calcium</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum magnesium</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum phosphorus</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum glucose</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood urea nitrogen (BUN)</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline in micromoles per liter (umol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum uric acid</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (umol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total bilirubin</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (umol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in alanine aminotransferase (ALT)</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline in international units per liter (IU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in aspartate transaminase (AST)</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (IU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in gamma-glutamyl transpeptidase (GGT)</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (IU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in alkaline phosphatase (ALP)</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (IU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum total protein</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline in grams per liter (g/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum albumin</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow up (week 14)</time_frame>
    <description>Change from baseline (g/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hematocrit</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow-up (week 14)</time_frame>
    <description>Change from baseline (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Measured at weeks 0,4,8,12,13 and follow-up (week 14)</time_frame>
    <description>Change from baseline (%)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcyrstalline cellulose (Avicel): provided in 5 capsules (350 mg each), twice daily (BID) prior to lunch and dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSP3 (2.25g)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSP3: provided in 3 capsules (750 mg each), plus 2 placebo capsules (350 mg each), twice daily (BID) prior to lunch and dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSP3 (3.75g)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSP3: provided in 5 capsules (750 mg each), twice daily (BID) prior to lunch and dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GSP3</intervention_name>
    <description>Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.</description>
    <arm_group_label>GSP3 (2.25g)</arm_group_label>
    <arm_group_label>GSP3 (3.75g)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Avicel (modified Cellulose)</intervention_name>
    <description>Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose</description>
    <arm_group_label>GSP3 (2.25g)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body Mass Index (BMI) ≥ 27 and ≤ 35 (at least 30% overweight and 30% obese subjects)&#xD;
&#xD;
          2. Ability to follow verbal and written instructions&#xD;
&#xD;
          3. Informed Consent Form signed by the subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. Absence of medically approved contraceptive methods in females of childbearing&#xD;
             potential (e.g., hysterectomy, non-oral contraceptive medications or intrauterine&#xD;
             device combined with a barrier method, two combined barrier methods such as diaphragm&#xD;
             and condom or spermicide; bilateral tubal ligation and vasectomy are not acceptable&#xD;
             contraceptive methods)&#xD;
&#xD;
          3. History of allergic reaction to carboxymethylcellulose, citric acid, modified&#xD;
             cellulose, microcrystalline cellulose, and gelatin&#xD;
&#xD;
          4. Administration of investigational products within 1 month prior to Screening Visit&#xD;
&#xD;
          5. Night-shift workers&#xD;
&#xD;
          6. Subjects who stopped smoking within 6 months prior to Screening Visit or considering&#xD;
             smoking cessation during the study&#xD;
&#xD;
          7. Subjects anticipating surgical intervention during the study&#xD;
&#xD;
          8. Known type 1 or type 2 diabetes&#xD;
&#xD;
          9. History of eating disorders including binge eating (except mild binge eater)&#xD;
&#xD;
         10. Weight change &gt; 3 kg within 3 months prior to and during the Screening period&#xD;
&#xD;
         11. Supine systolic blood pressure (SBP) &gt; 150 mm Hg and/or supine diastolic blood&#xD;
             pressure (DBP) &gt; 90 mm Hg&#xD;
&#xD;
         12. Angina, coronary bypass, or myocardial infarction within 6 months prior to Screening&#xD;
             Visit&#xD;
&#xD;
         13. History of gastroesophageal reflux disease&#xD;
&#xD;
         14. History of gastric or duodenal ulcer&#xD;
&#xD;
         15. History of gastroparesis&#xD;
&#xD;
         16. History of gastric bypass or any other gastric surgery&#xD;
&#xD;
         17. History of intragastric balloon&#xD;
&#xD;
         18. History of pancreatitis&#xD;
&#xD;
         19. History of hemorrhoids&#xD;
&#xD;
         20. History of malabsorption&#xD;
&#xD;
         21. Laxative users&#xD;
&#xD;
         22. History of hepatitis B or C&#xD;
&#xD;
         23. History of human immunodeficiency virus&#xD;
&#xD;
         24. History of cancer within the past 5 years (except adequately-treated localized basal&#xD;
             cell skin cancer or in situ uterine cervical cancer)&#xD;
&#xD;
         25. Any other clinically significant disease interfering with the assessments of Attiva,&#xD;
             according to the Investigator&#xD;
&#xD;
         26. Positive serum or urine pregnancy test(s) in females of childbearing potential&#xD;
&#xD;
         27. Plasma glucose ≥ 126 mg/dL (7.0 mmol/L)&#xD;
&#xD;
         28. Abnormal serum thyrotropin (TSH)&#xD;
&#xD;
         29. Serum triglycerides &gt; 500 mg/dL (5.65 mmol/L)&#xD;
&#xD;
         30. Positive test for drugs in the urine&#xD;
&#xD;
         31. Any relevant biochemical abnormality interfering with the assessments of Attiva,&#xD;
             according to the Investigator&#xD;
&#xD;
         32. Anti-obesity medications (including herbal preparations) within 1 month prior to&#xD;
             Screening Visit&#xD;
&#xD;
         33. Systemic corticosteroids within 1 month prior to Screening Visit&#xD;
&#xD;
         34. Thyroid hormones or preparations within 1 month prior to Screening Visit (except in&#xD;
             subjects on stable dose of replacement therapy for at least 1 month)&#xD;
&#xD;
         35. Any other medication known to cause weight loss or weight gain within 1 month prior to&#xD;
             Screening Visit&#xD;
&#xD;
         36. Medications treating hypertension within 1 month prior to Screening Visit&#xD;
&#xD;
         37. Medications treating dyslipidemia within 1 month prior to Screening Visit&#xD;
&#xD;
         38. Anticipated requirement for use of prohibited concomitant medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Heshmati, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gelesis, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hradec Králové</name>
      <address>
        <city>Hradec</city>
        <zip>500 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University</name>
      <address>
        <city>Prague</city>
        <zip>121 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cophenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federico University Hospital</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>weight loss</keyword>
  <keyword>body composition</keyword>
  <keyword>glycemic control</keyword>
  <keyword>satiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

